AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
GMED vs MSFT Fundamental Comparison
| Metric | GMED | MSFT |
|---|---|---|
| Revenue | $2.9B | $158.9B |
| Net Income | $537.9M | $66.2B |
| Net Margin | 18.3% | 41.7% |
| ROE | 11.8% | 16.9% |
| ROA | 10.1% | 10.0% |
| Current Ratio | 4.26x | 1.39x |
| Debt/Equity | 0.00x | 0.10x |
| EPS | $3.92 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
GMED vs MSFT: Frequently Asked Questions
Is GMED or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. GMED is rated BUY (78% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does GMED compare to MSFT fundamentally?
GLOBUS MEDICAL INC has ROE of 11.8% vs MICROSOFT CORP's 16.9%. Net margins are 18.3% vs 41.7% respectively.
Which stock pays higher dividends, GMED or MSFT?
GMED has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in GMED or MSFT for long term?
For long-term investing, consider that GMED has BUY rating with 78% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about GMED vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GMED vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.